Upgrade to SI Premium - Free Trial

Teva Pharma (TEVA) PT Raised to $48 at UBS

September 4, 2026 5:46 AM
UBS analyst Ashwani Verma raised the price target on Teva Pharma (NYSE: TEVA) to $48.00 (from $42.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change